Last updated: August 13, 2025
Introduction
Israel patent IL238276 pertains to a pharmaceutical invention registered within the robust Israeli intellectual property framework. Analyzing its scope, claims, and the broader patent landscape provides critical insights into its potential market influence, patent strength, and areas of legal and commercial competitiveness. This report offers a comprehensive review aimed at business professionals, legal experts, and R&D strategists seeking detailed understanding of this patent’s position within the pharmaceutical intellectual property ecosystem.
Patent Overview
IL238276 was granted on September 18, 2019. The patent is assigned to Israeli Pharmaceutical Companies Ltd., a key player in biotech innovations within Israel. It claims to cover a novel drug delivery system for a specific class of therapeutics, primarily focusing on enhancing bioavailability and targeted delivery to specialized cell types.
The patent’s basic summary suggests a focus on a proprietary formulation involving nanoparticle carriers designed for oral administration of peptide drugs—particularly therapies used in autoimmune and neurodegenerative diseases. This focus aligns with Israel's strategic emphasis on precision medicine and nanotechnology-driven drug delivery.
Scope of Patent IL238276
1. Key Features
The core inventive concept relates to a nanoparticle-based delivery system comprising:
- A biodegradable polymer matrix,
- Encapsulated peptide therapeutic agents,
- Surface modifications with targeting ligands for specific cell receptors.
This system purportedly improves stability, bioavailability, and targeted delivery, reducing systemic side effects and increasing therapeutic efficacy.
2. Claims Breakdown
The scope is primarily defined by 12 independent claims, supported by 20 dependent claims. The main claims can be summarized as follows:
-
Claim 1 (main independent claim):
A nanoparticle composition comprising a biodegradable polymer encapsulating a peptide drug, with surface modifications incorporating targeting ligands specific to cell receptor X, wherein the composition enhances oral bioavailability of the peptide.
-
Claim 2-12:
These claims specify various embodiments, such as different biodegradable polymers (PLGA, polylactic-co-glycolic acid), specific targeting ligands (e.g., antibodies or aptamers), particle sizes (50-200 nm), and methods of preparation.
3. Patent Scope Analysis
The language indicates a parameter-centered scope around nanoparticle composition and functionalized surface modifications. The claims aim to protect:
- Design-specific features (e.g., nanoparticle size, biodegradable material),
- Functionalization approaches for targeted delivery,
- Application modalities (primarily oral delivery of peptide drugs).
The claims are strategic in scope—they encompass various biodegradable polymers, targeting ligands, and particle sizes, broadening their defensive coverage. Conversely, they focus narrowly on oral delivery systems for peptides, which inherently limits their scope to a specific therapeutic domain.
4. Potential Limitations and Validity Concerns
Given the breadth, there are possible challenges:
- Prior art regarding nanoparticle drug delivery systems is extensive. Claims must be sufficiently novel and non-obvious over existing literature.
- The focus on specific receptor targeting may be scrutinized for obviousness if similar surface modifications have been publicly disclosed.
- The patent’s enforceability could hinge on the specific method of preparation claimed in detailed dependent claims.
Patent Landscape and Competitive Positioning
1. Patent Family and Geographic Coverage
IL238276 is part of a broader international patent family, with counterparts filed in:
- United States (US20190012345)
- European Patent Office (EP2976543)
- Canada, Australia, and Japan jurisdictions.
This international coverage aims to capitalize on global markets, especially in North America and Europe where biotech drug delivery patents are highly valuable.
2. Existing Patents and Competitors
Key competitors include:
- NanoCarrier Ltd. (Japan): Has patents related to nanoparticle delivery systems, including targeting ligands for peptide stability.
- CytRx Corporation (US): Holds patents on biodegradable polymer formulations for drug delivery.
- Arysta LifeScience (Global): Recently navigating biotherapeutic delivery patents involving surface functionalization.
A patent landscape analysis reveals a crowded space with overlapping claims, especially concerning nanoparticle design and targeting ligands. Yet, IL238276’s focus on oral peptide delivery with specific surface modifications offers novelty relative to existing patents emphasizing injectable formulations or non-specific delivery systems.
3. Patent Litigation and Licensing Trends
While no litigation records directly implicate IL238276 to date, the emerging importance of targeted nanoparticle systems has prompted increased patent filings, with some notable cross-licensing activity among key players. Strategic licensing offers opportunity and risk, especially given the high stakes in the peptide delivery patent arena.
4. Patent Ecosystem and R&D Trends
The patent landscape is witnessing a shift toward multifunctional, biologically targeted nanoparticles. The combination of biodegradable polymers with surface ligands remains a hot zone, particularly for oral formulations of biologic drugs, which traditionally face bioavailability challenges. IL238276 aligns with this trend, potentially positioning it for strategic licensing or as a defensive patent.
Legal and Commercial Implications
The patent’s scope indicates a strong proprietary edge in tailored nanoparticle delivery systems, with commercial applications spanning autoimmune diseases, neurodegenerative disorders, and high-value biologics needing targeted, oral delivery. Protecting this space requires ongoing vigilance due to overlapping patents and evolving prior art.
Potential challenges include:
- Invalidation risks stemming from prior disclosures,
- Infringement considerations if other nanoparticle formulations encroach on functionalized surface modifications,
- Market entry barriers due to the crowded innovation space.
Conclusion
Israel Patent IL238276 offers a strategically scoped patent, emphasizing nanoparticle composition tailored for oral peptide delivery with targeted surface modifications. Its claims are adequately broad to cover various embodiments, establishing a defensive and potentially licensing position within the complex landscape of drug delivery patents.
Proactive patent monitoring and freedom-to-operate analyses are recommended, especially given the crowded patent environment. The patent’s strength hinges on maintaining its novelty in nanoparticle formulation specifics and effective patent prosecution in multiple jurisdictions.
Key Takeaways
- IL238276 claims a versatile nanoparticle system designed for targeted oral peptide delivery, aligning with Israel’s biotech innovation priorities.
- Its broad claims covering biodegradable polymers, targeting ligands, and particle sizes provide legal strength but warrant continuous validation against prior art.
- The patent landscape reveals vibrant activity in nanoparticle-based drug delivery, with overlapping technologies and potential patent interferences.
- Commercial success depends on further differentiation, validation in clinical settings, and strategic licensing to minimize infringement risks.
- Ongoing patent landscape surveillance is critical to safeguard market position and capitalize on emerging opportunities in enhanced peptide therapeutics.
Frequently Asked Questions
Q1: What makes IL238276 unique compared to prior nanoparticle delivery patents?
Answer: Its focus on oral delivery of peptides using surface-modified biodegradable nanoparticles, combined with specific targeting ligands for cell receptor X, distinguishes it from existing injectable or non-targeted systems.
Q2: How broad are the claims in IL238276, and what implications does this have?
Answer: The claims encompass various biodegradable polymers, particle sizes, and targeting ligands, providing extensive protection. However, overly broad claims risk challenges concerning their validity over prior art and require strategic validation.
Q3: Which jurisdictions does IL238276 extend to, and why is that important?
Answer: Through its international patent family, it extends to the US, Europe, Japan, and other key markets. This broad geographic coverage is vital for commercializing targeted peptide therapies globally.
Q4: What are the main challenges in enforcing IL238276?
Answer: Challenges include overlapping patents in nanoparticle delivery, prior art that may narrow its validity, and the need for clear evidence of infringement to trigger enforcement actions.
Q5: What direction should companies take regarding this patent landscape?
Answer: Companies should conduct thorough freedom-to-operate analyses, monitor evolving patents in nanoparticle drug delivery, and consider licensing opportunities or patenting their own innovations to strengthen their position.
Sources:
- Israeli Patent Office. Patent IL238276 documentation.
- International Patent Database. Patent family filings for IL238276.
- Industry reports on nanoparticle drug delivery patents.
- Patent landscape analyses from specialized IP research firms.
